The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

被引：0
作者：
Xu, Jinyun [1 ,2 ]
Gu, Jiaowei [2 ]
Zhao, Yan [2 ]
Meng, Huihua [1 ]
Du, Li'an [1 ]
Zhang, Ruibo [2 ]
Jiang, Hao [2 ]
Luo, Jianming [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning, Guangxi, Peoples R China
[2] Hubei Univ Med, Taihe Hosp, Dept Pediat, Shiyan, Hubei, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 58期
关键词：
BIM; chronic myeloid leukemia; tyrosine kinase inhibitor; genetic polymorphism; drug resistance; DIAGNOSED CHRONIC-PHASE; PATIENTS RECEIVING IMATINIB; FOLLOW-UP; CYTOGENETIC RESPONSES; INTRINSIC RESISTANCE; 1ST-LINE TREATMENT; TYROSINE KINASE; BIM; DASATINIB; NILOTINIB;
D O I：
10.18632/oncotarget.21154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 East Asian patients were identified from these electronic databases. The methodological quality of one included trial was high, and the others were moderate. Meta-analysis showed that the rate of TKI resistance between the BIM deletion and wild-type group were no statistical significance (OR = 1.24, 95% CI 0.79-1.95). In conclusion, BIM deletion may not a predictor of TKI resistance in CML individuals in East Asia.
引用
收藏
页码：99041 / 99048
页数：8
相关论文
共 50 条
  • [21] Activity and Tolerability of Nilotinib A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant
    Koren-Michowitz, Maya
    le Coutre, Philipp
    Duyster, Justus
    Scheid, Christof
    Panayiotidis, Panayiotis
    Prejzner, Witold
    Rowe, Jacob M.
    Schwarz, Michaela
    Goldschmidt, Neta
    Nagler, Arnon
    [J]. CANCER, 2010, 116 (19) : 4564 - 4572
  • [22] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [23] Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis
    Gupta, Priyanka
    Banothu, Kiran Kumar
    Haldar, Partha
    Gupta, Aditya Kumar
    Meena, Jagdish Prasad
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (05) : 227 - 234
  • [24] MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
    Louati, N.
    Turki, F.
    Mnif, H.
    Frikha, R.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 39 - 48
  • [25] Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients
    Bianchini, Michele
    De Brasi, Carlos
    Gargallo, Patricia
    Gonzalez, Mariana
    Bengio, Raquel
    Larripa, Irene
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (04) : 292 - 300
  • [26] OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
    Koren-Michowitz, Maya
    Buzaglo, Zehavit
    Ribakovsky, Elena
    Schwarz, Michaela
    Pessach, Ilias
    Shimoni, Avichai
    Beider, Katia
    Amariglio, Ninette
    le Coutre, Philipp
    Nagler, Arnon
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (04) : 283 - 288
  • [27] Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia A Systematic Review and Meta-analysis
    Wang, Zhe
    Wang, Xiaoyu
    Wang, Zhen
    Feng, Yuyi
    Jia, Yaqin
    Jiang, Lili
    Xia, Yangliu
    Cao, Jun
    Liu, Yong
    [J]. JAMA NETWORK OPEN, 2021, 4 (07)
  • [28] Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia
    M Pocaly
    V Lagarde
    G Etienne
    J-A Ribeil
    S Claverol
    M Bonneu
    F Moreau-Gaudry
    V Guyonnet-Duperat
    O Hermine
    J V Melo
    M Dupouy
    B Turcq
    F-X Mahon
    J-M Pasquet
    [J]. Leukemia, 2007, 21 : 93 - 101
  • [29] Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia
    Pocaly, M.
    Lagarde, V.
    Etienne, G.
    Ribeil, J-A
    Claverol, S.
    Bonneu, M.
    Moreau-Gaudry, F.
    Guyonnet-Duperat, V.
    Hermine, O.
    Melo, J. V.
    Dupouy, M.
    Turcq, B.
    Mahon, F-X
    Pasquet, J-M
    [J]. LEUKEMIA, 2007, 21 (01) : 93 - 101
  • [30] First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    Chen, Kang-Kang
    Du, Tai-Feng
    Wu, Ku-Sheng
    Yang, Wei
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3891 - 3910
12345